Gökoğlan, Ecem

Profile Picture
Name Variants
Gokoglan, Ecem
Job Title
Araştırma Görevlisi
Email Address
ecem.gokoglan@fbu.edu.tr
Main Affiliation
Eczacılık Meslek Bilimleri Bölümü
Status
Website
ORCID ID
0000-0002-2488-9698
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
JHT-9133-2023
Files
photo_309893.jpg.JPG (2.21 MB)

Filters

20231
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Article
    Citation - WoS: 1
    Citation - Scopus: 1
    Synthesis and Investigation of Cytotoxic Effects of Compounds Derived From Flurbiprofen
    (Elsevier, 2023) Gökoğlan, Ecem; Küçükgüzel, Şükriye Güniz; Bedir, Ipek; Yelekci, Kemal; Telci, Dilek; Kucukguzel, S. Guniz; Eczacılık Meslek Bilimleri Bölümü
    New flurbiprofen derivatives containing 1,2,4-triazoline-5-thione (4) and thioethers (5a-r) were synthesized in this study. The structures of synthesized compounds were characterized by spectral methods (FT-IR, 1H NMR, 13C NMR) and 19F NMR (only compound 5l), besides elemental analysis. In addition, molecular binding of these compounds to the human methionine aminopeptidase 2 enzyme was performed using AutoDock 4.2, the software product of the research, computationally. All synthesized compounds were evaluated for cytotoxic effect against MDA-MB231 triple-negative breast cancer cell line by using WST-1 Cell Viability and Proliferation assay. Doxorubicin is in the anthracycline class and is an antineoplastic agent. It is used to provide regression in common neoplastic conditions such as breast carcinoma. Due to the cardiovascular side effects of doxorubicin, a combination study was conducted with the (& PLUSMN;)(R,S)-3-{1-[2-fluoro-(1,1 & PRIME;-biphenyl)-4-yl]ethyl}-4-methyl-5-{[2(trifluoromethyl)benzyl]thio}-4H-1,2,4-triazole (5l) with promising cytotoxic effects. As a result of the combination, it was shown as 7% MDA-MB231 cell viability. Therefore, based on the evaluations, a better cytotoxic effect was achieved with the 5l combination depending on the low dose of doxorubicin.